Skip to content

US · CRDF · BIOTECHNOLOGY

Cardiff Oncology, Inc. (CRDF) intrinsic value and stock valuation

$0.85as of 2026-11-21 · Mkt cap 62.67M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cardiff Oncology, Inc. DCF and intrinsic value

InvestorsCraft values CRDF with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CRDF’s statements →

Cardiff Oncology, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 cardiffoncology.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$590K+9.8% 5y CAGRd
20112025
Net income
-$-45.85M
20112025
Free cash flow
-$-37.97M
20112025
Total equity
$45.4M-18.7% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$590K$680K$490K$390K$360K
Operating income-$-48.96M-$-48.65M-$-45.41M-$-39.9M-$-28.86M
Net income-$-45.85M-$-45.43M-$-41.44M-$-38.7M-$-28.29M
EPSd-$-685.97K-$-953.41K-$-927.48K-$-887.61K-$-724.83K
Operating cash flow-$-37.92M-$-37.69M-$-30.89M-$-33.82M-$-23.04M
Capital expenditure-$-40K-$-80K-$-580K-$-890K-$-200K
Free cash flow-$-37.97M-$-37.77M-$-31.47M-$-34.71M-$-23.25M
Total assets$61.9M$97.2M$81.6M$116.2M$149.5M
Total debt$830K$1.52M$2.15M$2.71M$3.12M
Net debt-$-16.64M-$-49.95M-$-19.51M-$-13.63M-$-8.82M
Total equity$45.4M$83M$69.7M$106.3M$140.4M
Cash and short-term investments$58.3M$91.8M$74.8M$105.3M$140.8M
Income statement
20252024202320222021
Revenue$590K$680K$490K$390K$360K
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$590K$680K$490K$390K$360K
Research and development expenses$35.3M$36.9M$32.9M$27.1M$17.4M
Selling, general and administrative expenses$14.2M$12.5M$13M$13.2M$11.8M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$49.6M$49.3M$45.9M$40.3M$29.2M
Cost and expenses$49.6M$49.3M$45.9M$40.3M$29.2M
Interest income$3.1M$3.26M$4.07M$1.58M$260K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$900K$400K$400K$240K$450K
Ebitda-$-44.95M-$-45.03M-$-41.04M-$-38.47M-$-27.84M
Operating income-$-48.96M-$-48.65M-$-45.41M-$-39.9M-$-28.86M
Total other income/expenses, net$3.11M$3.22M$3.97M$1.2M$560K
Income before tax-$-45.85M-$-45.43M-$-41.44M-$-38.7M-$-28.29M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-45.85M-$-45.43M-$-41.44M-$-38.7M-$-28.29M
Weighted average shares outstanding$66.8M$47.7M$44.7M$43.6M$39M
Weighted average diluted shares outstanding$66.8M$47.7M$44.7M$43.6M$39M
Balance sheet
20252024202320222021
Cash and short-term investments$58.3M$91.8M$74.8M$105.3M$140.8M
Net receivables$180K$770K$290K$770K$540K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$60.1M$95.1M$77.4M$111.3M$146.1M
Property, plant and equipment, net$1.21M$2.07M$2.95M$3.52M$3.18M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.76M$2.14M$4.22M$4.91M$3.42M
Total assets$61.9M$97.2M$81.6M$116.2M$149.5M
Accounts payable$8.09M$4.82M$1.97M$1.96M$1.44M
Short-term debt$730K$710K$690K$680K$550K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$16.4M$13.4M$10.4M$7.81M$6.56M
Long-term debt$100K$810K$1.46M$2.04M$2.57M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$100K$810K$1.46M$2.04M$2.57M
Capital lease obligations$830K$1.52M$2.15M$2.71M$3.12M
Total liabilities$16.5M$14.2M$11.9M$9.85M$9.13M
Common stock$10K$10K$0.00$0.00$0.00
Retained earnings-$-430.03M-$-384.18M-$-339.54M-$-298.1M-$-259.81M
Accumulated other comprehensive income (loss)$50K$30K-$-70K-$-400K-$-140K
Total equity$45.4M$83M$69.7M$106.3M$140.4M
Total investments$40.8M$40.3M$53.2M$88.9M$128.9M
Total debt$830K$1.52M$2.15M$2.71M$3.12M
Net debt-$-16.64M-$-49.95M-$-19.51M-$-13.63M-$-8.82M
Cash flow statement
20252024202320222021
Net income-$-45.85M-$-45.43M-$-41.44M-$-38.7M-$-28.29M
Depreciation and amortization$900K$400K$400K$240K$450K
Stock-based compensation$5.69M$4.76M$4.51M$4.26M$3.23M
Change in working capital$2.18M$3.17M$6.57M-$-380K-$-1.79M
Accounts receivable$590K-$-480K$480K-$-240K-$-210K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$2.2M$2.98M$2.83M$1.35M$720K
Net cash provided by operating activities-$-37.92M-$-37.69M-$-30.89M-$-33.82M-$-23.04M
Investments in property, plant and equipment-$-40K-$-80K-$-580K-$-890K-$-200K
Acquisitions, net$0.00$0.00$0.00-$-110K$200K
Net cash used for investing activities$1.34M$13.7M$36.2M$38.2M-$-131.45M
Common stock issued$2.58M$53.4M$0.00$70K$34.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00-$-410K-$-20K
Net cash used for financing activities$2.58M$53.8M$0.00$70K$35.5M
Net change in cash-$-34M$29.8M$5.31M$4.4M-$-119.04M
Cash at end of period$17.5M$51.5M$21.7M$16.4M$11.9M
Operating cash flow-$-37.92M-$-37.69M-$-30.89M-$-33.82M-$-23.04M
Capital expenditure-$-40K-$-80K-$-580K-$-890K-$-200K
Free cash flow-$-37.97M-$-37.77M-$-31.47M-$-34.71M-$-23.25M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cardiff Oncology, Inc.

        Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

        CEO
        Mani Mohindru
        Employees
        31
        Beta
        1.44

        Explore

        Frequently asked questions

        What is the intrinsic value of Cardiff Oncology, Inc. (CRDF)?

        InvestorsCraft does not currently publish an intrinsic value for CRDF. How the IC value is calculated.

        Is CRDF undervalued?

        InvestorsCraft does not publish an undervaluation signal for CRDF at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.